Press Release No. 069/KFCP-DIR/PR/XII/21
Jakarta, December 22, 2021. PT Kalbe Farma Tbk (“Kalbe”) in collaboration with the Indonesian Doctors Association Research Institute (“IDI Research Institute”) announced the winner of the 2021 Indonesian Doctors' Cipta Karya (AKCDI) Award. The AKCDI which has been held since 2019 is an award for doctors who are interested in the field of scientific work and is stated in the form of an award for the best copyrighted works which include: basic medical, clinical, and epidemiological research, as well as evidence based-case reports (EBCR). This year, 3 winners of the 2019 AKCDI have been selected, they are: Taufik Akbar with the theme "Effectiveness of Implantation of Secretomes of Mesenchymal Stem Cells from Adipose Tissue, Bone Marrow, and Umbilical Cord Against Callus Growth in Critical Long Bone Defects in Sprague Dawley Mice" for unpublished manuscripts ; Zulvikar Syambani Ulhaq with the theme “The Level of Ig Anti-Rbd Sars-Cov-2 After Two Doses of Coronavac Vaccine” for the published manuscript; Talita Clarissa Sinatra, “The Relationship of Vitamin D Deficiency (25(OH)D) to Necrotizing Enterocolitis and Respiratory Distress Syndrome in Premature Infants” for Evidence-based case report (EBCR),
“This year's AKCDI is the third collaboration time between IDI Research Institute and Kalbe that aims to foster the interest of doctors in Indonesia to produce scientific works. We hope that the AKCDI program will have a positive impact on improving the competence of doctors as well as developing research and knowledge in the health sector or health technology. " said Dr. Daeng M Faqih, SH, MH, Chairman of IDI's Executive Board of the 2018-2021 period.
"Kalbe continues to be committed to contributing to the world of research in Indonesia, particularly research in the field of health," said Mulia Lie, Director of Pharma of PT Kalbe Farma Tbk. "Through AKCDI 2021, Kalbe wants to give appreciation to doctors who have dedicated themselves to the advancement of research in Indonesia," added Mulia.
Mulia added that the implementation of AKCDI is a collaboration between Kalbe and the IDI Research Institute. Since 2018, Kalbe has signed a cooperation agreement with the IDI Research Institute to support research activities including awarding the best research doctors in Indonesia.
"Through collaboration with IDI, we hope that Kalbe can make a real contribution in enriching research in the Health sector, as well as strengthen collaboration between Academics, Business and Government," said Mulia Lie
"The jury has selected 65 files of incoming research results, both those that have been published or not. We added a category with criteria for Evidence-based case report (EBCR) which is a method of writing or reporting cases or clinical problems with an evidence-based approach," said dr. Marhaen Hardjo, M. Biomed, PhD, Chair of the IDI Research Institute who is also a member of the AKCDI 2021 jury.
Marhaen added that the EBCR category that distinguishes it from ordinary research manuscripts is a manuscript in the form of clinical cases or scenarios related to clinical innovations carried out during the COVID-19 pandemic.
The board of juries of AKCDI 2021 is coordinated by the IDI Research Institute, with the judges consisting of Dr. dr. Wawang Setiawan Sukarya, Sp.OG(K), MARS, MH.Kes, dr. Marhaen Hardjo, M. Biomed, PhD, Dr. dr. Rahyussalim, SpOT(K), dr. Muhammad Akbar Sp.S(K)., Ph.D., DFM, Dr. dr. Anwar Santoso, Sp.JP(K), dr. Titi Savitri Prihatiningsih, M.Med.Ed.,PhD and dr. Renan Sukmawan, ST, SpJP, Ph.D.
Aside from the support for the IDI Research Institute in organizing the 2021 AKCDI, Kalbe is also collaborating with the National Research and Innovation Agency (BRIN) and universities in providing research grants in Indonesia through the Research and Technology BRIN-Kalbe Science Award (RKSA) program. The research grant is directed toward researches that have the readiness to be commercialized, therefore the research results can be enjoyed by the general public.
Kalbe at a glance
PT Kalbe Farma Tbk ("Kalbe") was established in 1966 and is one of the largest listed pharmaceutical companies in Southeast Asia. Kalbe has four main divisions that handle reliable and varied brand portfolio: prescription medicines (Cefspan, Brainact, Broadced, etc.); health product division that handles over-the-counter medication (Promag, Mixagrip, Komix, Woods, Fatigon, etc.); multivitamins (Fatigon, H2, XonCe, Hevit-C, JossC1000, etc.); as well as supplement and ready-to-consume drinks (Hydro Coco, Extra Joss); nutrition division (ChilKid, Prenagen, Diabetasol, Zee, etc,); and distribution & logistics division.
Kalbe has also developed EMOS, a digital service ecosystem for the community that is B2B; and KlikDokter that is a B2C service. EMOS is an order management application system that makes it easy for distribution channels to manage stock or supply chains; while KlikDokter is a digital platform for health services, especially telemedicine that provides health consultations and health products needed by the community.
Kalbe currently has approximately 40 subsidiaries and 15 production facilities with international standard and employs approximately 16,000 employees dispersed across more than 76 branches throughout Indonesia. Since 1991, Kalbe is listed on the Indonesia Stock Exchange (IDX: KLBF).